CT and Fusion PET-CT for Diagnosis, Staging and Follow-Up

  • Aparna Balachandran
  • Priya Bhosale
  • Chuslip Charnsangavej
Reference work entry


Pancreatic cancer is the fourth leading cause of cancer related deaths. Surgery is the only chance for cure in patients with pancreatic adenocarcinoma. The role of imaging in patients with a pancreatic mass is to accurately detect, characterize and stage the pancreatic mass if malignancy is suspected. In case of suspected pancreatic adenocarcinoma, the detection of vascular involvement and metastases is crucial to prevent unnecessary surgery. The TNM staging along with the category of “borderline resectable” tumors, the role of CT in primary tumor detection and in the staging of pancreatic adenocarcinoma is covered in this chapter. The emerging role of fusion PET-CT in the evaluation of pancreatic masses is described in this chapter.


Positron Emission Tomography Pancreatic Cancer Standard Uptake Value Superior Mesenteric Artery Pancreatic Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71–96.CrossRefPubMedGoogle Scholar
  2. 2.
    Katz MH, Hwang R, Fleming JB, Evans DB: Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 2008;58(2):111–125.CrossRefPubMedGoogle Scholar
  3. 3.
    Pakzad F, Groves AM, Ell PJ: The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 2006;36:248–256.CrossRefPubMedGoogle Scholar
  4. 4.
    Greene FL, Page DL, Fleming ID, et al.: Exocrine pancreas. In AJCC Cancer Staging Manual, 6th edn. Greene, FL Page, DL Fleming, ID et al.: New York: Springer, 2002, pp. 157–164.Google Scholar
  5. 5.
    Quon A, Chang ST, Chin F, et al.: Initial evaluation of (18)F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur J Nucl Med Mol Imaging 2008;35:527–531.CrossRefPubMedGoogle Scholar
  6. 6.
    Shreve PD, Gross MD: Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med 1997;38:1305–1310.PubMedGoogle Scholar
  7. 7.
    Herlin G, Persson B, Bergstrom M, et al.: 11C-harmine as a potential PET tracer for ductal pancreas cancer: in vitro studies. Eur Radiol 2003;13:729–733.PubMedGoogle Scholar
  8. 8.
    Sabbah EN, Kadouche J, Ellison D, et al.: In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer. Nucl Med Biol 2007;34:293–304.CrossRefPubMedGoogle Scholar
  9. 9.
    Warburg O: On the origin of cancer cells. Science 1956;123:309–314.CrossRefPubMedGoogle Scholar
  10. 10.
    Zanzi IRW, Vinciguerra V: Positron emission tomography (PET) imaging in patients with carcinoma of the pancreas. In Proceedings of American Society of Clinical Oncology, 1990:9:A434.Google Scholar
  11. 11.
    Klever P, Bares R, Fass J, et al.: PET with fluorine-18 deoxyglucose for pancreatic disease. Lancet 1992;340:1158–1159.CrossRefPubMedGoogle Scholar
  12. 12.
    Zimny M, Bares R, Fass J, et al.: Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997;24:678–682.PubMedGoogle Scholar
  13. 13.
    Inokuma T, Tamaki N, Torizuka T, et al.: Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995;195:345–352.PubMedGoogle Scholar
  14. 14.
    Rose DM, Delbeke D, Beauchamp RD, et al.: 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999;229:729–737; discussion 737–728.CrossRefPubMedGoogle Scholar
  15. 15.
    Koyama K, Okamura T, Kawabe J, et al.: Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001;15:217–224.CrossRefPubMedGoogle Scholar
  16. 16.
    Sendler A, Avril N, Helmberger H, Stollfuss J, Weber W, Bengel F, Schwaiger M, Roder JD, Siewert JR: Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000;24(9):1121–1129.Google Scholar
  17. 17.
    Gambhir SS, Czernin J, Schwimmer J, et al.: A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S–93S.PubMedGoogle Scholar
  18. 18.
    Lytras D, Connor S, Bosonnet L, Jayan R, Evans J, Hughes M, Garvey CJ, Ghaneh P, Sutton R, Vinjamuri S, Neoptolemos JP: Positron Emission Tomography does not add to Computed Tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 2005;22(1–2):55–61.CrossRefPubMedGoogle Scholar
  19. 19.
    Delbeke D, Pinson CW: Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004;11:4–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Mansour JC, Schwartz L, Pandit-Taskar N, et al.: The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg 2006;10:1354–1360.CrossRefPubMedGoogle Scholar
  21. 21.
    Sperti C, Pasquali C, Decet G, et al.: F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 2005;9:22–28; discussion 28–29.CrossRefPubMedGoogle Scholar
  22. 22.
    DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, Ciaccia D, Lane KA, Maglinte D, Kopecky K, LeBlanc J, McHenry L, Madura J, Aisen A, Cramer H, Cummings O, Sherman S: Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004;141(10):753–763.PubMedGoogle Scholar
  23. 23.
    Agarwal B, Abu-Hamda E, Molke KL, Correa AM, Ho L: Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 2004;99(5):844–850.CrossRefPubMedGoogle Scholar
  24. 24.
    Tamm EP, Loyer EM, Faria SC, Evans DB, Wolff RA, Charnsangavej C: Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. Abdom Imaging 2007;32(5):660–667.CrossRefPubMedGoogle Scholar
  25. 25.
    Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA: Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13(8):1035–1046.CrossRefPubMedGoogle Scholar
  26. 26.
    Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF: Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206(5):833–846.CrossRefPubMedGoogle Scholar
  27. 27.
    Loyer EM, David CL, Dubrow RA, Evans DB, Charnsangavej C: Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging 1996;21(3):202–206.CrossRefPubMedGoogle Scholar
  28. 28.
    Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J: Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997;168(6):1439–1443.PubMedGoogle Scholar
  29. 29.
    Nakayama Y, Yamashita Y, Kadota M, Takahashi M, Kanemitsu K, Hiraoka T, Hirota M, Ogawa M, Takeya M: Vascular encasement by pancreatic cancer: correlation of CT findings with surgical and pathologic results. J Comput Assist Tomogr 2001;25(3):337–342.CrossRefPubMedGoogle Scholar
  30. 30.
    Li H, Zeng MS, Zhou KR, Jin DY, Lou WH: Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr 2005;29(2):170–175.CrossRefPubMedGoogle Scholar
  31. 31.
    Horton KM, Fishman EK: Multidetector CT angiography of pancreatic carcinoma: part I, evaluation of arterial involvement. AJR Am J Roentgenol 2002;178(4):827–831.PubMedGoogle Scholar
  32. 32.
    Lepanto L, Arzoumanian Y, Gianfelice D, Perreault P, Dagenais M, Lapointe R, Létourneau R, Roy A: Helical CT with CT angiography in assessing periampullary neoplasms: identification of vascular invasion. Radiology 2002;222(2):347–352.CrossRefPubMedGoogle Scholar
  33. 33.
    O'Malley ME, Boland GW, Wood BJ, Fernandez-del Castillo C, Warshaw AL, Mueller PR: Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. AJR Am J Roentgenol 1999;173(6):1513–1518.PubMedGoogle Scholar
  34. 34.
    Valls C, Andía E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, Serrano T, Garcia-Borobia F, Jorba R: Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002;178(4):821–826.PubMedGoogle Scholar
  35. 35.
    Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB Jr.: MDCT in Pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. AJR Am J Roentgenol 2004;182(2):419–425.PubMedGoogle Scholar
  36. 36.
    Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Ginès MA, Real MI, Gilabert R, Quintó L, Trilla A, Feu F, Montanyà X, Fernández-Cruz L, Navarro S: Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 2004;99(3):492–501.CrossRefPubMedGoogle Scholar
  37. 37.
    Karmazanovsky G, Fedorov V, Kubyshkin V, Kotchatkov A: Pancreatic head cancer: accuracy of CT in determination of resectability. Abdom Imaging 2005;30(4):488–500.CrossRefPubMedGoogle Scholar
  38. 38.
    Raptopoulos V, Steer ML, Sheiman RG, Vrachliotis TG, Gougoutas CA, Movson JS: The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer: correlation with findings at surgery. AJR Am J Roentgenol 1997;168(4):971–977.PubMedGoogle Scholar
  39. 39.
    Diehl SJ, Lehmann KJ, Sadick M, Lachmann R, Georgi M: Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998;206(2):373–378.PubMedGoogle Scholar
  40. 40.
    Prokesch RW, Chow LC, Beaulieu CF, Nino-Murcia M, Mindelzun RE, Bammer R, Huang J, Jeffrey RB Jr.: Local staging of pancreatic carcinoma with multi-detector row CT: use of curved planar reformations initial experience. Radiology 2002;225(3):759–765.CrossRefPubMedGoogle Scholar
  41. 41.
    Fukushima H, Itoh S, Takada A, Mori Y, Suzuki K, Sawaki A, Iwano S, Satake H, Ota T, Ikeda M, Ishigaki T: Diagnostic value of curved multiplanar reformatted images in multislice CT for the detection of resectable pancreatic ductal adenocarcinoma. Eur Radiol 2006;16(8):1709–1718.CrossRefPubMedGoogle Scholar
  42. 42.
    Brügel M, Link TM, Rummeny EJ, Lange P, Theisen J, Dobritz M: Assessment of vascular invasion in pancreatic head cancer with multislice spiral CT: value of multiplanar reconstructions. Eur Radiol 2004;14(7):1188–1195.CrossRefPubMedGoogle Scholar
  43. 43.
    Zamboni GA, Kruskal JB, Vollmer CM, Baptista J, Callery MP, Raptopoulos VD: Pancreatic adenocarcinoma: value of multidetector CT angiography in preoperative evaluation. Radiology 2007;245(3):770–778.CrossRefPubMedGoogle Scholar
  44. 44.
    Fletcher JW, Djulbegovic B, Soares HP, et al.: Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480–508.CrossRefPubMedGoogle Scholar
  45. 45.
    Roche CJ, Hughes ML, Garvey CJ, Campbell F, White DA, Jones L, Neoptolemos JP: CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol 2003;180(2):475–480.PubMedGoogle Scholar
  46. 46.
    Japan Pancreas Society. General Rules for the Study of Pancreatic Cancer, 4th edn. Kanehara, Tokyo: 1993:25–35.Google Scholar
  47. 47.
    Bakkevold KE, Kambestad B: Staging of carcinoma of the pancreas and ampulla of Vater. Tumor [T], lymph node [N], and distant metastasis [M] as prognostic factors. Int J Pancreatol 1995;17(3):249–259.PubMedGoogle Scholar
  48. 48.
    Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N: Nodal involvement is strongest predictor of poor survival in patients with invasive adenocarcinoma of the head of the pancreas. Hepatogastroenterology 2006;53(69):447–451.PubMedGoogle Scholar
  49. 49.
    Maithel SK, Khalili K, Dixon E, Guindi M, Callery MP, Cattral MS, Taylor BR, Gallinger S, Greig PD, Grant DR, Vollmer CM Jr.: Impact of regional lymph node evaluation in staging patients with periampullary tumors. Ann Surg Oncol 2007;14(1):202–210.CrossRefPubMedGoogle Scholar
  50. 50.
    Müller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B: Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging. Radiology 1994;190(3):745–751.PubMedGoogle Scholar
  51. 51.
    Zeman RK, Cooper C, Zeiberg AS, Kladakis A, Silverman PM, Marshall JL, Evans SR, Stahl T, Buras R, Nauta RJ, Sitzmann JV, al-Kawas F: TNM staging of pancreatic carcinoma using helical CT. AJR Am J Roentgenol 1997;169(2):459–464.PubMedGoogle Scholar
  52. 52.
    Midwinter MJ, Beveridge CJ, Wilson JB, Bennett MK, Baudouin CJ, Charnley RM: Correlation between spiral computed tomography, endoscopic ultrasonography and findings at operation in pancreatic ampullary tumours. Br J Surg 1999;86:189–193.CrossRefPubMedGoogle Scholar
  53. 53.
    Diederichs CG, Staib L, Vogel J, et al.: Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000;20:109–116.CrossRefPubMedGoogle Scholar
  54. 54.
    Bares R, Klever P, Hauptmann S, et al.: F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994;192:79–86.PubMedGoogle Scholar
  55. 55.
    Bares R, Dohmen BM, Cremerius U, et al.: Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma. Radiologe 1996;36:435–440.CrossRefPubMedGoogle Scholar
  56. 56.
    Kamisawa T, Isawa T, Koike M, Tsuruta K, Okamoto A: Hematogenous metastases of pancreatic ductal carcinoma. Pancreas 1995;11(4):345–349.CrossRefPubMedGoogle Scholar
  57. 57.
    Lee YT, Tatter D: Carcinoma of the pancreas and periampullary structures. Pattern of metastasis at autopsy. Arch Pathol Lab Med 1984;108(7):584–587.PubMedGoogle Scholar
  58. 58.
    Mao C, Domenico DR, Kim K, Hanson DJ, Howard JM: Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg 1995;130(2):125–134.PubMedGoogle Scholar
  59. 59.
    Fenchel S, Boll DT, Fleiter TR, Brambs HJ, Merkle EM: Multislice helical CT of the pancreas and spleen. Eur J Radiol 2003;45(Suppl. 1):S59–S72.CrossRefPubMedGoogle Scholar
  60. 60.
    Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer 2006;106(7):1624–1633.CrossRefPubMedGoogle Scholar
  61. 61.
    Bluemke DA, Cameron JL, Hruban RH, Pitt HA, Siegelman SS, Soyer P, Fishman EK: Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Radiology 1995;197(2):381–385.PubMedGoogle Scholar
  62. 62.
    Manak E, Merkel S, Klein P, Papadopoulos T, Bautz WA, Baum U: Resectability of pancreatic adenocarcinoma: assessment using multidetector-row computed tomography with multiplanar reformations. Abdom Imaging 2007 Oct 13.Google Scholar
  63. 63.
    Frohlich A, Diederichs CG, Staib L, et al.: Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999;40:250–255.PubMedGoogle Scholar
  64. 64.
    Nishiyama Y, Yamamoto Y, Yokoe K, et al.: Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med 2005;19:491–497.CrossRefPubMedGoogle Scholar
  65. 65.
    Howard TJ, Krug JE, Yu J, et al.: A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006;10:1338–1345; discussion 1345–1336.CrossRefPubMedGoogle Scholar
  66. 66.
    Brown KM, Siripurapu V, Davidson M, et al.: Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg 2008;195:318–321.CrossRefPubMedGoogle Scholar
  67. 67.
    Sperti C, Pasquali C, Chierichetti F, et al.: 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003;7:953–959; discussion 959–960.CrossRefPubMedGoogle Scholar
  68. 68.
    Maisey NR, Webb A, Flux GD, et al.: FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 2000;83:287–293.CrossRefPubMedGoogle Scholar
  69. 69.
    Wakabayashi H, Nishiyama Y, Otani T, et al.: Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 2008;14:64–69.CrossRefPubMedGoogle Scholar
  70. 70.
    Bang S, Chung HW, Park SW, et al.: The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006;40:923–929.CrossRefPubMedGoogle Scholar
  71. 71.
    Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP: Current standards of surgery for pancreatic cancer. Br J Surg 2004;91(11):1410–1427.CrossRefPubMedGoogle Scholar
  72. 72.
    Karpoff HM, Klimstra DS, Brennan MF, Conlon KC: Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 2001;136:44–47.CrossRefPubMedGoogle Scholar
  73. 73.
    Ihse I, Anderson H, Andre’n-Sandberg A: Total pancreatectomy for cancer of the pancreas: is it appropriate? World J Surg 1996;20:288–294.CrossRefPubMedGoogle Scholar
  74. 74.
    Dalla Valle R, Mancini C, Crafa P, Passalacqua R: Pancreatic carcinoma recurrence in the remnant pancreas after a pancreaticoduodenectomy. JOP 2006;7(5):473–477.PubMedGoogle Scholar
  75. 75.
    Tryka AF, Brooks JR: Histopathology in the evaluation of total pancreatectomy for ductal carcinoma. Ann Surg 1979;190:373–381.CrossRefPubMedGoogle Scholar
  76. 76.
    Launois B, Franci J, Bardaxoglou E, Ramee MP, Paul JL, Malledant Y, et al.: Total pancreatectomy for ductal adenocarcinoma of the pancreas with special reference to resection of the portal vein and multicentric cancer. World J Surg 1993;17:122–126.CrossRefPubMedGoogle Scholar
  77. 77.
    Ruf J, Lopez Hanninen E, Oettle H, et al.: Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005;5:266–272.CrossRefPubMedGoogle Scholar
  78. 78.
    Nakamoto Y, Higashi T, Sakahara H, et al.: Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547–2554.CrossRefPubMedGoogle Scholar
  79. 79.
    Shreve PD: Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998;25:259–264.CrossRefPubMedGoogle Scholar
  80. 80.
    Casneuf V, Delrue L, Kelles A, et al.: Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg 2007;70:331–338.PubMedGoogle Scholar
  81. 81.
    Lemke AJ, Niehues SM, Hosten N, et al.: Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions – a prospective study with 104 patients. J Nucl Med 2004;45:1279–1286.PubMedGoogle Scholar
  82. 82.
    Heinrich S, Goerres GW, Schafer M, et al.: Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005;242:235–243.CrossRefPubMedGoogle Scholar
  83. 83.
    Ruf J, Lopez Hanninen E, Bohmig M, et al.: Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology 2006;6:512–519.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Aparna Balachandran
    • 1
  • Priya Bhosale
    • 1
  • Chuslip Charnsangavej
    • 2
  1. 1.Department of Diagnostic RadiologyM.D. Anderson Cancer CenterHoustonUSA
  2. 2.University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations